Fresenius Sells Controlling Stake in Vamed Rehab Business to PAI

Fresenius SE has agreed to sell a controlling stake in the rehabilitation business of its Vamed unit to French private equity firm PAI Partnersas the German healthcare company further trims its portfolio.

PAI will own 67% of the entity, which has an enterprise value of €853 million ($914 million), Fresenius said in a statement on Thursday.

Since taking the helm of the company in October 2022, Fresenius Chief Executive Officer Michael Sen has sought to simplify its strategy after years of complaints from investors that it was too complex. He’s given priority to its Kabi intravenous-drug unit and Helios ...